Clinical Trial Search

Primary: Maximal Change in UPDRS Part III From Predose to Postdose on Day 1 — -22.0; -12.5; -11.2; -15.2 score on a scale

Primary: Melatonin Levels — 0.89; 0.84; 0.9; 0.68 pg/mL

Primary: Use of FOBT ColoCARE Home Kit — 14; 2; 14; 0 participants

Primary: Area Under the Curve Following Administration of Oral Valacyclovir Suspension 20 mg/kg Every 8 Hours — 28.8 mgxh/l

Primary: Patient Internalized Stigma Towards Medicaid for Opioid Use Disorder (MOUDs) Over the Course of the Project — 15; 11; 14; 8 score on a scale — p=0.32

Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants

Primary: Primary Performance Endpoint — 151 Participants

Primary: Glucose — -21.55; 1.92 mg/dL

Primary: Change in Kessler Psychological Distress Scale (K10) Score — 6.4; 4.5 score on a scale

Primary: Session Attendance — 39 Participants

Primary: Stressor-evoked Oxygen Consumption in mL/(kg·Min) (Stress - Baseline) — 0.265; 0.287 mL/(kg·min)

Primary: Percent of Exams With Lesions Identified — 14.3; 17.3; 0; 21.1 percent of exams

Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…

Primary: Mean Area Under the Net Head Acceleration vs. Time Curve During Direct Loading, With Anticipatory Bracing - Linear Motion. — .895; 1.069; .873; .903 meters per second…

Primary: Apixaban vs. Enoxaparin - Number of Participants With Bleeding Events — 1; 1 Participants